Novartis to buy Regulus Therapeutics for up to $1.7 billion

Regulus Therapeutics

30/04/2025 12:10

April 30 (Reuters) - Regulus Therapeutics RGLS.O said on Wednesday Swiss drugmaker Novartis NOVN.S has agreed to buy the drug developer for up to $1.7 billion to gain access to its experimental kidney disease drug.

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)

 ((Mariam.ESunny@thomsonreuters.com;))